Does the media refer more to HRMY or RLMD?

In the previous week, Relmada Therapeutics had 9 more articles in the media than Harmony Biosciences. MarketBeat recorded 20 mentions for Relmada Therapeutics and 11 mentions for Harmony Biosciences. Relmada Therapeutics' average media sentiment score of 0.92 beat Harmony Biosciences' score of 0.83 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relmada Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better earnings & valuation, RLMD or MLYS?

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A Mineralys Therapeutics N/A N/A -$154.65M -$2.05 N/A

Is RLMD or MLYS more profitable?

Mineralys Therapeutics' return on equity of -56.35% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -59.03% -53.97% Mineralys Therapeutics N/A -56.35% -54.78%

Does the media refer more to RLMD or MLYS?

In the previous week, Relmada Therapeutics had 1 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 20 mentions for Relmada Therapeutics and 19 mentions for Mineralys Therapeutics. Relmada Therapeutics' average media sentiment score of 0.92 beat Mineralys Therapeutics' score of 0.18 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Mineralys Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, RLMD or HCM?

HUTCHMED has higher revenue and earnings than Relmada Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A HUTCHMED $548.51M 3.87 $456.91M N/A N/A

Is RLMD or HCM more profitable?

HUTCHMED's return on equity of 0.00% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -59.03% -53.97% HUTCHMED N/A N/A N/A

Does the media favor RLMD or HCM?

In the previous week, Relmada Therapeutics had 16 more articles in the media than HUTCHMED. MarketBeat recorded 20 mentions for Relmada Therapeutics and 4 mentions for HUTCHMED. Relmada Therapeutics' average media sentiment score of 0.92 beat HUTCHMED's score of 0.73 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive HUTCHMED 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, GHRS or RLMD?

GH Research is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$1.00 N/A Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A

Is GHRS or RLMD more profitable?

GH Research's return on equity of -20.07% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -20.07% -19.41% Relmada Therapeutics N/A -59.03% -53.97%

Does the media prefer GHRS or RLMD?

In the previous week, GH Research had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 23 mentions for GH Research and 20 mentions for Relmada Therapeutics. GH Research's average media sentiment score of 0.94 beat Relmada Therapeutics' score of 0.92 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relmada Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger earnings & valuation, RLMD or RAPP?

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A Rapport Therapeutics N/A N/A -$111.48M -$3.04 N/A

Is RLMD or RAPP more profitable?

Rapport Therapeutics' return on equity of -29.02% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -59.03% -53.97% Rapport Therapeutics N/A -29.02% -27.37%

Does the media refer more to RLMD or RAPP?

In the previous week, Rapport Therapeutics had 5 more articles in the media than Relmada Therapeutics. MarketBeat recorded 25 mentions for Rapport Therapeutics and 20 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.92 beat Rapport Therapeutics' score of 0.64 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Rapport Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Relmada Therapeutics (RLMD) Competitors

$4.86 +0.15 (+3.07%)

As of 02:32 PM Eastern

Compare

RLMD vs. HRMY, MLYS, HCM, GHRS, and RAPP

Should you buy Relmada Therapeutics stock or one of its competitors? Relmada Therapeutics's main competitors and comparable companies include Harmony Biosciences (HRMY), Mineralys Therapeutics (MLYS), HUTCHMED (HCM), GH Research (GHRS), and Rapport Therapeutics (RAPP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Relmada Therapeutics compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and Relmada Therapeutics (NASDAQ:RLMD) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Harmony Biosciences currently has a consensus target price of $45.50, suggesting a potential upside of 17.91%. Relmada Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 146.66%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Relmada Therapeutics had 9 more articles in the media than Harmony Biosciences. MarketBeat recorded 20 mentions for Relmada Therapeutics and 11 mentions for Harmony Biosciences. Relmada Therapeutics' average media sentiment score of 0.92 beat Harmony Biosciences' score of 0.83 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relmada Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Harmony Biosciences has a net margin of 18.88% compared to Relmada Therapeutics' net margin of 0.00%. Harmony Biosciences' return on equity of 20.06% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	18.88%	20.06%	14.15%
Relmada Therapeutics	N/A	-59.03%	-53.97%

Harmony Biosciences has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Harmony Biosciences has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.59	$158.69M	$3.08	12.53
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

Summary

Harmony Biosciences beats Relmada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Relmada Therapeutics compare to Mineralys Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Mineralys Therapeutics (NASDAQ:MLYS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Mineralys Therapeutics' return on equity of -56.35% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-59.03%	-53.97%
Mineralys Therapeutics	N/A	-56.35%	-54.78%

Relmada Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 146.66%. Mineralys Therapeutics has a consensus target price of $49.33, suggesting a potential upside of 86.88%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Relmada Therapeutics is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

Relmada Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

In the previous week, Relmada Therapeutics had 1 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 20 mentions for Relmada Therapeutics and 19 mentions for Mineralys Therapeutics. Relmada Therapeutics' average media sentiment score of 0.92 beat Mineralys Therapeutics' score of 0.18 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Mineralys Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Relmada Therapeutics beats Mineralys Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Relmada Therapeutics compare to HUTCHMED?

Relmada Therapeutics (NASDAQ:RLMD) and HUTCHMED (NASDAQ:HCM) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

HUTCHMED has higher revenue and earnings than Relmada Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
HUTCHMED	$548.51M	3.87	$456.91M	N/A	N/A

Relmada Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 146.66%. HUTCHMED has a consensus price target of $14.87, indicating a potential upside of 22.31%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Relmada Therapeutics is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
HUTCHMED	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

HUTCHMED's return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-59.03%	-53.97%
HUTCHMED	N/A	N/A	N/A

Relmada Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Relmada Therapeutics had 16 more articles in the media than HUTCHMED. MarketBeat recorded 20 mentions for Relmada Therapeutics and 4 mentions for HUTCHMED. Relmada Therapeutics' average media sentiment score of 0.92 beat HUTCHMED's score of 0.73 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
HUTCHMED	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Relmada Therapeutics beats HUTCHMED on 8 of the 12 factors compared between the two stocks.

How does Relmada Therapeutics compare to GH Research?

GH Research (NASDAQ:GHRS) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

GH Research has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

GH Research's return on equity of -20.07% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.07%	-19.41%
Relmada Therapeutics	N/A	-59.03%	-53.97%

56.9% of GH Research shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 41.6% of GH Research shares are owned by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

GH Research is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

GH Research presently has a consensus target price of $45.00, indicating a potential upside of 57.01%. Relmada Therapeutics has a consensus target price of $12.00, indicating a potential upside of 146.66%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, GH Research had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 23 mentions for GH Research and 20 mentions for Relmada Therapeutics. GH Research's average media sentiment score of 0.94 beat Relmada Therapeutics' score of 0.92 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relmada Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

GH Research beats Relmada Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Relmada Therapeutics compare to Rapport Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Rapport Therapeutics (NASDAQ:RAPP) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Relmada Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

45.2% of Relmada Therapeutics shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rapport Therapeutics' return on equity of -29.02% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-59.03%	-53.97%
Rapport Therapeutics	N/A	-29.02%	-27.37%

Relmada Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 146.66%. Rapport Therapeutics has a consensus price target of $61.57, indicating a potential upside of 27.77%. Given Relmada Therapeutics' higher possible upside, research analysts clearly believe Relmada Therapeutics is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A

In the previous week, Rapport Therapeutics had 5 more articles in the media than Relmada Therapeutics. MarketBeat recorded 25 mentions for Rapport Therapeutics and 20 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.92 beat Rapport Therapeutics' score of 0.64 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Rapport Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Relmada Therapeutics beats Rapport Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Relmada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLMD vs. The Competition

Export

Metric	Relmada Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$518.95M	$11.87B	$7.03B	$13.08B
Dividend Yield	N/A	2.70%	2.58%	10.74%
P/E Ratio	-5.41	785.65	269.09	25.22
Price / Sales	N/A	930.95	642.14	105.23
Price / Cash	N/A	67.97	70.59	50.58
Price / Book	4.12	10.59	13.28	6.25
Net Income	-$57.38M	$2.77B	$3.45B	$347.70M
7 Day Performance	-9.40%	0.57%	2.17%	1.87%
1 Month Performance	-24.57%	-0.18%	1.25%	1.03%
1 Year Performance	756.21%	164.86%	68.01%	19.90%

Relmada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLMD Relmada Therapeutics	2.2774 of 5 stars	$4.87 +3.1%	$12.00 +146.7%	+702.7%	$518.95M	N/A	N/A	10	Earnings Report Analyst Revision
HRMY Harmony Biosciences	4.3616 of 5 stars	$38.62 +8.5%	$42.63 +10.4%	+12.1%	$2.24B	$868.45M	15.57	200	Analyst Downgrade Gap Up
MLYS Mineralys Therapeutics	2.7834 of 5 stars	$26.21 +1.7%	$49.33 +88.2%	+100.2%	$2.16B	N/A	N/A	28	Trending News Earnings Report Analyst Revision
HCM HUTCHMED	2.5762 of 5 stars	$11.59 +0.3%	$14.87 +28.3%	-20.1%	$2.02B	$548.51M	N/A	1,796
GHRS GH Research	3.2345 of 5 stars	$29.28 +3.8%	$40.78 +39.3%	+149.1%	$2.01B	N/A	N/A	10	Trending News Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLMD) was last updated on 8/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relmada Therapeutics (RLMD) Competitors

RLMD vs. HRMY, MLYS, HCM, GHRS, and RAPP

How does Relmada Therapeutics compare to Harmony Biosciences?

Summary

How does Relmada Therapeutics compare to Mineralys Therapeutics?

Summary

How does Relmada Therapeutics compare to HUTCHMED?

Summary

How does Relmada Therapeutics compare to GH Research?

Summary

How does Relmada Therapeutics compare to Rapport Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relmada Therapeutics (RLMD) Competitors

RLMD vs. HRMY, MLYS, HCM, GHRS, and RAPP

How does Relmada Therapeutics compare to Harmony Biosciences?

Do analysts recommend HRMY or RLMD?

Do insiders & institutionals have more ownership in HRMY or RLMD?

Does the media refer more to HRMY or RLMD?

Is HRMY or RLMD more profitable?

Which has more risk & volatility, HRMY or RLMD?

Which has better valuation & earnings, HRMY or RLMD?

Summary

How does Relmada Therapeutics compare to Mineralys Therapeutics?

Do institutionals and insiders have more ownership in RLMD or MLYS?

Is RLMD or MLYS more profitable?

Do analysts prefer RLMD or MLYS?

Which has better earnings & valuation, RLMD or MLYS?

Which has more risk & volatility, RLMD or MLYS?

Does the media refer more to RLMD or MLYS?

Summary

How does Relmada Therapeutics compare to HUTCHMED?

Which has better valuation and earnings, RLMD or HCM?

Do analysts recommend RLMD or HCM?

Is RLMD or HCM more profitable?

Which has more volatility and risk, RLMD or HCM?

Do institutionals & insiders believe in RLMD or HCM?

Does the media favor RLMD or HCM?

Summary

How does Relmada Therapeutics compare to GH Research?

Which has more volatility & risk, GHRS or RLMD?

Is GHRS or RLMD more profitable?

Do institutionals and insiders believe in GHRS or RLMD?

Which has better valuation and earnings, GHRS or RLMD?

Do analysts recommend GHRS or RLMD?

Does the media prefer GHRS or RLMD?

Summary

How does Relmada Therapeutics compare to Rapport Therapeutics?

Which has more volatility and risk, RLMD or RAPP?

Do institutionals & insiders hold more shares of RLMD or RAPP?

Is RLMD or RAPP more profitable?

Do analysts recommend RLMD or RAPP?

Which has stronger earnings & valuation, RLMD or RAPP?

Does the media refer more to RLMD or RAPP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools